Related references
Note: Only part of the references are listed.Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Vaishali Sanchorawala et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)
Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis
Raphael Szalat et al.
LEUKEMIA (2021)
Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis
Jose Acevedo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis
Brian Lilleness et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
Robert A. Kyle et al.
MAYO CLINIC PROCEEDINGS (2019)
Ten-year survivors in AL amyloidosis: characteristics and treatment pattern
Eli Muchtar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75
M. Hasib Sidiqi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
M. Hasib Sidiqi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Epidemiology of AL amyloidosis: a real-world study using US claims data
Tiffany P. Quock et al.
BLOOD ADVANCES (2018)
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
H. Landau et al.
LEUKEMIA (2017)
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time
Vaishali Sanchorawala et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Geriatric assessment is superior to oncologists' clinical judgement in identifying frailty
Lene Kirkhus et al.
BRITISH JOURNAL OF CANCER (2017)
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival
N. Tandon et al.
BONE MARROW TRANSPLANTATION (2017)
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
Vaishali Sanchorawala et al.
BLOOD (2015)
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Anita D'Souza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
M. A. Gertz et al.
BONE MARROW TRANSPLANTATION (2013)
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115
V. Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2013)
High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center
Stephanie B. Tsai et al.
BLOOD (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
Morie A. Gertz et al.
LEUKEMIA & LYMPHOMA (2010)
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
David C. Seldin et al.
BLOOD (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome
PN Mollee et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2004)
Share Paper
